Cargando…

Targeting multiple genes containing long mononucleotide A-T repeats in lung cancer stem cells

BACKGROUND: Intratumour heterogeneous gene expression among cancer and cancer stem cells (CSCs) can cause failure of current targeted therapies because each drug aims to target the function of a single gene. Long mononucleotide A-T repeats are cis-regulatory transcriptional elements that control man...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhummaphan, Narumol, Pin-on, Piyapat, Phiboonchaiyanan, Preeyaporn Plaimee, Siriluksana, Jirattha, Aporntewan, Chatchawit, Chanvorachote, Pithi, Mutirangura, Apiwat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8166091/
https://www.ncbi.nlm.nih.gov/pubmed/34059086
http://dx.doi.org/10.1186/s12967-021-02902-6
Descripción
Sumario:BACKGROUND: Intratumour heterogeneous gene expression among cancer and cancer stem cells (CSCs) can cause failure of current targeted therapies because each drug aims to target the function of a single gene. Long mononucleotide A-T repeats are cis-regulatory transcriptional elements that control many genes, increasing the expression of numerous genes in various cancers, including lung cancer. Therefore, targeting A-T repeats may dysregulate many genes driving cancer development. Here, we tested a peptide nucleic acid (PNA) oligo containing a long A-repeat sequence [A(15)] to disrupt the transcriptional control of the A-T repeat in lung cancer and CSCs. METHODS: First, we separated CSCs from parental lung cancer cell lines. Then, we evaluated the role of A-T repeat gene regulation by counting the number of repeats in differentially regulated genes between CSCs and the parental cells of the CSCs. After testing the dosage and effect of PNA-A15 on normal and cancer cell toxicity and CSC phenotypes, we analysed genome-wide expression to identify dysregulated genes in CSCs. RESULTS: The number of A-T repeats in genes differentially regulated between CSCs and parental cells differed. PNA-A15 was toxic to lung cancer cells and CSCs but not to noncancer cells. Finally, PNA-A15 dysregulated a number of genes in lung CSCs. CONCLUSION: PNA-A15 is a promising novel targeted therapy agent that targets the transcriptional control activity of multiple genes in lung CSCs. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-021-02902-6.